The global retinal disorder treatment market size is expected to reach USD 15.8 billion by 2026, according to a new report by Radiant Insights, Inc., registering a CAGR of 7.6% over the forecast period. Increasing prevalence and incidence of retinal disorders is considered to be the primary growth driver.
According to data published in the NCBI in 2018, around 18.0% of diabetic patients in India suffer from diabetic retinopathy. Similarly, National Eye Institute estimates that by 2030 and 2050, around 10 and 14 million people respectively will suffer from diabetic retinopathy in America. Based on an article published by WebMD in 2019, age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in U.S., occurring in more than 10% of the population aged 65-74 years. Moreover, the NCBI estimates that by 2040, individuals with early and late AMD will range between 14.9-21.5 million and 3.9-4.8 million respectively in Europe.
Download Free Sample Report @ https://www.radiantinsights.com/research/retinal-disorder-treatment-market/request-sample
Increasing geriatric population is also anticipated to be a major factor governing the overall market. According to data published in the World Population Prospects: 2019 Revision, around 1 in 11 and 1 in 4 people living in North America and Europe, respectively, will be aged 65 years and above by 2050.
Growing awareness of retinal disorders is also expected to propel market growth over the forecast period. For instance, the Institut de la Macula started an awareness campaign on age-related macular degeneration in 2019. The primary aim of this campaign is to create awareness about the disease, benefits of early detection, and available treatment options in the market.
Further key findings from the report suggest:
• By type, macular degeneration held the dominant share in 2018 and is estimated to be the fastest growing segment over the forecast period. Rising prevalence of macular degeneration globally is the major factor driving the segment
• In 2018, dry macular degeneration emerged as the largest segment and is expected to register the highest CAGR through 2026
• On the basis of dosage form, eye solutions formed the leading segment in 2018. Eye drops are estimated to be the fastest growing segment over the forecast period owing to strong presence of pipeline products
• Based on distribution channel, hospital pharmacies held the largest share in 2018 while online pharmacy will exhibit the fastest growth by 2026
• North America held the dominant revenue share in 2018 owing to presence of key players in the market. Asia Pacific is estimated to witness the fastest CAGR of 9.5% from 2019 to 2026
• Research and development and collaborations are some of the crucial strategies adopted by players in the market.
Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/retinal-disorder-treatment-market
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.2.1. Purchased database
1.2.2. Radiant Insights internal database
1.2.3. Secondary sources & third party perspectives
1.2.4. Primary research
1.3. Information analysis
1.3.1. Data analysis models
1.4. Market formulation & data visualization
1.5. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Retinal Disorder Treatment Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis, by Stage
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increasing prevalence of retinal disorders
3.4.1.2. Presence of pipeline products
3.4.1.3. Increasing geriatric population
3.4.1.4. Rising awareness of retinal disorders
3.4.2. Market Restraint Analysis
3.4.2.1. High cost of treatment drugs
3.5. Retinal disorder treatment: Market Analysis Tools
3.5.1. Industry Analysis - Porter's
3.5.1.1. Supplier Power (Moderate due to large number of manufacturers)
3.5.1.2. Buyer Power (High due to increasing prevalence of retinal disorders)
3.5.1.3. Substitution Threat (High due to presence external substitutes)
3.5.1.4. Threat from new entrant (Moderate due to brand recognition of the existing players)
3.5.1.5. Competitive rivalry (High due to rigorous competition among key players)
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.3.1. Joint Ventures
3.5.3.2. Mergers & Acquisitions
3.5.3.3. Licensing & Partnership
3.5.3.4. Technology Collaborations
3.5.3.5. Strategic Divestments
Chapter 4. Retinal Disorder Treatment Market: Segment Analysis, By Type, 2014 - 2026 (USD Million)
4.1. Definitions & Scope
4.2. Type Market Share Analysis, 2018 & 2026
4.3. Segment Dashboard
4.4. Global Retinal Disorder Treatment Market, By Type, 2014 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following
4.5.1. Macular Degeneration
4.5.1.1. Dry Macular Degeneration
4.5.1.2. Wet Macular Degeneration
4.5.2. Diabetic Retinopathy
4.5.3. Others
Continued…
Read all Reports of this category @ https://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco; State: California; Country: United States
Email: [email protected]
Website: https://www.radiantinsights.com/
Retinal Disorder Treatment Market: IntroductionAccording to the report, the global retinal disorder treatment market was valued at ~US$ 9.2 Bn in 2018 and is projected to expand at a CAGR of ~8% from 2019 to 2027.
Retinal disorders include macular degeneration, diabetic retinopathy, diabetes macular edema, and retinal vein occlusion.
It is caused by damage to the blood vessels in the retina.
North America dominated the retinal disorder treatment market in 2018 and the trend is anticipated to continue during the forecast period.
Increase in prevalence of other retinal diseases also helps to fuel the growth of this market.
For instance, 93 million people have diabetic retinopathy, 21 million people are suffering from diabetic macular edema, and 28 million cases of vision-threatening diabetic retinopathy have been reported.
Retinal Disorders Treatment Market report published by Value Market Research, which studies the future outlook of the market.
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the retinal disorders treatment market include Santen Pharmaceutical Co., Ltd., REGENERON, Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., and Pfizer, Inc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Retinal Disorders Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/retinal-disorders-treatment-market/download-sampleMarket DynamicsThe rise in adult and diabetic patient’s population across the globe will boost the retinal disease therapeutics market.
In addition, the increase in R activities in developing countries is bound to boost the market growth globally as the prevalence of the retinal disorder is increasing in both developed and developing regions.
Further, the rise in the support offered by government and non-profitable organizations may have a positive impact on the market.
